Opinion
Video
Considerations Regarding Bridging Therapy for B-ALL CAR T-Cell Treatment
Experts discuss the routine initiation of bridging therapy between leukapheresis and chimeric antigen receptor (CAR) T-cell infusion at their center; the pharmacist’s role in implementing this procedure; collaboration with the team on agent choice, dosage, and administration; and monitoring for disease control and adverse events as well as the observed impact of bridging therapy on outcomes post CAR T-cell therapy.
Video content above is prompted by the following:
At your center, is bridging therapy routinely initiated during the interval between leukapheresis and CAR T-cell infusion?
- If so, as a pharmacist, what is your role in implementing this procedure?
- With whom on the team do you communicate on choice of agent, dosage, administration frequency, and monitoring for disease control and adverse events?
- What impact of bridging therapy have you observed on outcomes post CAR T-cell therapy?
Latest CME
View All
Video
18th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies
Apr 8th 2025 - May 14th 2025
online-activity
Video
Updates and Innovations in Nonopioid Pain Management Strategies for Breast Cancer Patients Postsurgical Intervention
Apr 7th 2025 - Apr 8th 2026
online-activity
Video
Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | Arkansas
Apr 3rd 2025 - May 9th 2025
online-activity
Related Content
.png?fit=crop&auto=format)
.jpg?fit=crop&auto=format)
